Alpha Cognition Inc. Common Stock (ACOG) 은(는) 상장 기업입니다 금융 섹터의 Financial - Conglomerates 산업에서 운영. 본사 소재지는 Vancouver, BC, 캐나다. 현재 CEO는 Michael E. McFadden.
ACOG 을(를) 보유 IPO 날짜 2024-11-12, 5 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $102.82M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
